Intra-Cellular Therapies Inc. | Large-cap | Healthcare
$131.87
0.00%
| Intra-Cellular Stock Comparison:
Intra-Cellular vs ZoetisIntra-Cellular vs Haleon Plc - ADRIntra-Cellular vs United TherapeuticsIntra-Cellular vs NeurocrineIntra-Cellular vs ViatrisIntra-Cellular vs S&P 500 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Dec 2024

Income Metrics

Revenue 199.2M
Gross Profit 178.8M 89.76%
Operating Income -29.2M -14.66%
Net Income -16.9M -8.48%

Balance Sheet Metrics

Total Assets 1.4B
Total Liabilities 218.5M
Shareholders Equity 1.1B
Debt to Equity 0.19

Cash Flow Metrics

Operating Cash Flow -16.9M
Free Cash Flow -12.7M

Revenue & Profitability Trend

Intra-Cellular Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i680.5M462.2M249.1M81.7M22.5M
Cost of Goods Sold i57.0M33.7M20.4M8.0M1.9M
Gross Profit i623.5M428.4M228.7M73.7M20.6M
Gross Margin % i91.6%92.7%91.8%90.2%91.6%
Operating Expenses
Research & Development i236.1M180.1M134.7M88.8M65.8M
Selling, General & Administrative i504.5M409.9M358.8M272.6M186.4M
Other Operating Expenses i-351.0K-2.2M-1.2M-2.1M-282.0K
Total Operating Expenses i740.3M587.8M492.3M359.4M251.9M
Operating Income i-116.7M-159.4M-263.6M-285.7M-231.2M
Operating Margin % i-17.2%-34.5%-105.8%-349.6%-1,026.3%
Non-Operating Items
Interest Income i42.5M20.3M7.4M1.6M4.2M
Interest Expense i-----
Other Non-Operating Income-----
Pre-tax Income i-74.2M-139.0M-256.2M-284.1M-227.0M
Income Tax i473.0K636.0K6.0K6.0K14.0K
Effective Tax Rate % i0.0%0.0%0.0%0.0%0.0%
Net Income i-74.7M-139.7M-256.3M-284.1M-227.0M
Net Margin % i-11.0%-30.2%-102.9%-347.7%-1,007.5%
Key Metrics
EBITDA i-116.2M-158.9M-263.0M-285.2M-230.7M
EPS (Basic) i$-0.72$-1.46$-2.72$-3.50$-3.23
EPS (Diluted) i$-0.72$-1.46$-2.72$-3.50$-3.23
Basic Shares Outstanding i10313101795881729940466708125339470364800
Diluted Shares Outstanding i10313101795881729940466708125339470364800

Income Statement Trend

Intra-Cellular Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i306.9M147.8M148.6M92.4M60.0M
Short-term Investments i694.1M350.2M443.3M320.0M597.4M
Accounts Receivable i166.5M114.0M75.2M20.2M10.8M
Inventory i26.3M11.6M23.9M7.9M7.1M
Other Current Assets111.8M42.4M45.2M25.4M14.2M
Total Current Assets i1.3B667.8M738.0M467.3M690.9M
Non-Current Assets
Property, Plant & Equipment i14.9M14.6M16.7M25.1M28.5M
Goodwill i-----
Intangible Assets i-----
Long-term Investments-----
Other Non-Current Assets44.7M45.9M86.0K86.0K86.1K
Total Non-Current Assets i59.5M60.5M16.8M22.6M26.4M
Total Assets i1.4B728.3M754.8M489.9M717.3M
Liabilities
Current Liabilities
Accounts Payable i26.1M11.5M10.4M8.7M5.5M
Short-term Debt i4.2M3.6M4.6M6.7M5.5M
Current Portion of Long-term Debt-----
Other Current Liabilities-----
Total Current Liabilities i205.7M123.5M83.2M53.4M36.9M
Non-Current Liabilities
Long-term Debt i12.7M13.3M15.5M18.7M23.6M
Deferred Tax Liabilities i-----
Other Non-Current Liabilities-----
Total Non-Current Liabilities i12.7M13.3M15.5M18.7M23.6M
Total Liabilities i218.5M136.9M98.7M72.0M60.5M
Equity
Common Stock i11.0K10.0K9.0K8.0K8.0K
Retained Earnings i-1.7B-1.6B-1.5B-1.2B-937.1M
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i1.1B591.4M656.1M417.9M656.9M
Key Metrics
Total Debt i17.0M16.9M20.0M25.4M29.1M
Working Capital i1.1B544.3M654.7M413.9M654.1M

Balance Sheet Composition

Intra-Cellular Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i-74.7M-139.7M-256.3M-284.1M-227.0M
Depreciation & Amortization i508.0K528.0K656.0K533.0K528.0K
Stock-Based Compensation i64.0M52.8M43.0M34.3M24.1M
Working Capital Changes i-53.2M-65.3M-68.7M-7.3M-19.6M
Operating Cash Flow i-63.3M-151.5M-281.2M-256.4M-221.7M
Investing Activities
Capital Expenditures i-322.0K-269.0K-778.0K-325.0K-267.0K
Acquisitions i-----
Investment Purchases i-739.7M-415.3M-759.2M-224.6M-755.6M
Investment Sales i404.9M521.1M631.6M505.2M275.6M
Investing Cash Flow i-335.2M105.5M-128.4M280.3M-480.3M
Financing Activities
Share Repurchases i-----
Dividends Paid i-----
Debt Issuance i-----
Debt Repayment i-----
Financing Cash Flow i543.1M0433.7M0652.7M
Free Cash Flow i-73.5M-124.5M-271.0M-259.9M-230.3M
Net Change in Cash i144.7M-46.0M24.1M24.0M-49.3M

Cash Flow Trend

Intra-Cellular Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -183.15
Forward P/E 507.19
Price to Book 12.20
Price to Sales 20.63
PEG Ratio 507.19

Profitability Ratios

Profit Margin -10.97%
Operating Margin -14.66%
Return on Equity -8.58%
Return on Assets -6.96%

Financial Health

Current Ratio 6.36
Debt to Equity 1.48
Beta 0.46

Per Share Data

EPS (TTM) $-0.73
Book Value per Share $10.81
Revenue per Share $6.60

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
itci14.0B-183.1512.20-8.58%-10.97%1.48
Zoetis 65.3B25.3613.1452.77%27.83%137.01
Haleon Plc - ADR 43.6B21.445.449.38%13.81%53.41
United Therapeutics 13.6B11.761.9019.30%40.36%0.00
Neurocrine 13.2B39.324.8813.39%13.88%18.18
Viatris 12.5B235.800.80-19.77%-24.57%94.78

Financial data is updated regularly. All figures are in the company's reporting currency.